期刊
MEDICINAL RESEARCH REVIEWS
卷 21, 期 5, 页码 356-381出版社
JOHN WILEY & SONS INC
DOI: 10.1002/med.1014
关键词
vancomycin; teicoplanin; ramoplanin; synthesis
资金
- NCI NIH HHS [CA 41101] Funding Source: Medline
Vancomycin, teicoplanin, and ramoplanin are potent glycopeptide antibiotics that act by inhibiting bacterial cell wall biosynthesis. The former are used clinically as the antibiotics of last resort for the treatment of methicillin-resistant Staphylococcus aureus and the latter is a promising new antibiotic that is not susceptible to the emerging bacterial resistance to vancomycin and teicoplanin. A summary of our recent total synthesis of the vancomycin aglycon, our first and second generation total syntheses of the teicoplanin aglycon, and our progress on the total synthesis of the ramoplanins is presented. This work lays the foundation for ongoing structure-function studies on the antibiotics that may clarify or define their site and mechanism of action leading to the development of improved or reengineered antibiotics. (C) 2001 John Wiley & Sons, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据